Pacific Beach Enters Into Agreement With Pharma Company

Pacific Beach BioSciences has granted non-exclusive rights to a pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage product.

Reportedly, the rights to the antifungal platform that was acquired by Pacific Beach BioSciences, includes several anti-fungal targets with the lead program focusing on novel glucan synthesis inhibitors.

James Rock, interim president and CEO of Pacific Beach, said: “This is the first licensing agreement Pacific Beach BioSciences has entered into since acquisition of the worldwide rights to an extensive anti-fungal platform. We hope to further exploit the opportunities in this platform through our research efforts.

“Our early development work has suggested that our lead compounds could demonstrate acceptable oral bioavailability in addition to broad spectrum anti-fungal activity including activity against Aspergillus and Candida strains of fungi.”